Venetoclax combined with azacitidine in treatment of acute megakaryoblastic leukemia transformed from primary myelofibrosis: report of 1 case and review of literature

WEI Xiaofang; FENG Youfan; DING Guosheng; FU Yuan; CHEN Yang; ZHANG Qike

doi:10.16766/j.cnki.issn.1674-4152.003441

Volume 22 Issue 3

Mar. 2024

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of General Practice > 2024 > 22(3): 526-529

WEI Xiaofang, FENG Youfan, DING Guosheng, FU Yuan, CHEN Yang, ZHANG Qike. Venetoclax combined with azacitidine in treatment of acute megakaryoblastic leukemia transformed from primary myelofibrosis: report of 1 case and review of literature[J]. Chinese Journal of General Practice, 2024, 22(3): 526-529. doi: 10.16766/j.cnki.issn.1674-4152.003441

Citation:

WEI Xiaofang, FENG Youfan, DING Guosheng, FU Yuan, CHEN Yang, ZHANG Qike. Venetoclax combined with azacitidine in treatment of acute megakaryoblastic leukemia transformed from primary myelofibrosis: report of 1 case and review of literature[J]. Chinese Journal of General Practice, 2024, 22(3): 526-529. doi: 10.16766/j.cnki.issn.1674-4152.003441

Citation:

WEI Xiaofang, FENG Youfan, DING Guosheng, FU Yuan, CHEN Yang, ZHANG Qike. Venetoclax combined with azacitidine in treatment of acute megakaryoblastic leukemia transformed from primary myelofibrosis: report of 1 case and review of literature[J]. Chinese Journal of General Practice, 2024, 22(3): 526-529. doi: 10.16766/j.cnki.issn.1674-4152.003441

PDF( 618 KB)

Venetoclax combined with azacitidine in treatment of acute megakaryoblastic leukemia transformed from primary myelofibrosis: report of 1 case and review of literature

doi: 10.16766/j.cnki.issn.1674-4152.003441

1.
Department of Hematology, Gansu Provincial Hospital, Lanzhou, Gansu 730000, China

Funds:

18GSSY4-34

22JR5RA660

Received Date: 2023-01-02
Available Online: 2024-05-27

Abstract

Abstract

We retrospectively analyzed the clinical data of an elderly patient of acute megakaryoblastic leukemia transformed from primary myelofibrosis treated with venetoclax combined with azacitidine in Gansu Provincial People' s Hospital and reviewed the relevant literature. This patient, a 72-year-old man, was diagnosed with primary myelofibrosis and was transformed to acute megakaryoblastic leukemia after 2 years of treatment with ruxolitinib, then given venetoclax combined with azacitidine. After the first course of treatment, the patient had partial remission of bone marrow and clinical improvement significantly. After the second course of treatment, although the bone marrow had complete remission and flow minimal residual disease (MRD) was negative, agranulocytosis persisted for up to 45 days and finally died due to infection.
- Venetoclax,
- Azacitidine,
- Primary myelofibrosis,
- Acute megakaryoblastic leukemia

FullText(HTML)

References(24)

References

[1]	GUPTA V, WOLLESCHAK D, HASSELBALCH H, et al. Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose finding study[J]. Blood Adv, 2020, 4(13): 3063-3071. doi: 10.1182/bloodadvances.2019001212
[2]	HOW J, HOBBS G S. A practical guide for using myelofibrosis prognostic models in the clinic[J]. J Natl Compr Canc Netw, 2020, 18(9): 1271-1278. doi: 10.6004/jnccn.2020.7557
[3]	SHAHIN O A, CHIFOTIDES HT, BOSE P, et al. Accelerated phase of myeloproliferative neoplasms[J]. Acta Haematol, 2021, 144(5): 484-499. doi: 10.1159/000512929
[4]	MCNULTY M, CRISPINO J D. Acute megakaryocytic leukemia[J]. Csh Perspect Med, 2020, 10(2): a034884-a034899. DOI: 10.1101/cshperspect.a034884.
[5]	ESTEY E, KARP J E, EMADI A, et al. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?[J]. Leukemia, 2020, 34(3): 671-681. doi: 10.1038/s41375-019-0704-5
[6]	VALLAPUREDDY R R, MUDIREDDY M, PENNA D, et al. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model[J]. Blood Cancer J, 2019, 9(2): 12-19. doi: 10.1038/s41408-019-0175-y
[7]	TEFFERI A, LASHO T L, JIMMA T, et al. One thousand patients with primary myelofibrosis: the Mayo clinic experience[J]. Mayo Clin Proc, 2012, 87(1): 25-33. doi: 10.1016/j.mayocp.2011.11.001
[8]	PASQUIER F, CABAGNOLS X, SECARDIN L, et al. Myeloproliferative neoplasms; JAK2 signaling pathway as a central target for therapy[J]. Clin Lymphoma Myeloma Leuk, 2014, 14(S3): S23-35.
[9]	尹春荣, 翁巍, 侯海珠, 等. JAK2V617F 基因突变与BCR/ABL阴性骨髓增殖性肿瘤的临床相关性分析[J]. 中华全科医学, 2016, 14(8): 1299-1301. doi: 10.16766/j.cnki.issn.1674-4152.2016.08.017 YIN C R, WENG W, HOU H Z, et al. JAK2V617F mutation and myeloproliferative neoplasms with BCR/ABL negative gene clinical correlation analysis[J]. Chinese Journal of General Practice, 2016, 14(8): 1299-1301. doi: 10.16766/j.cnki.issn.1674-4152.2016.08.017
[10]	PERNER F, PERNER C, ERNST T, et al. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation[J]. Cells, 2019, 8(8): 854-872. doi: 10.3390/cells8080854
[11]	PASCA S, CHIFOTIDES H T, VERSTOVSEK S, et al. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN[J]. Int Rev Cell Mol Biol, 2022, 366: 83-124.
[12]	HAHN A W, LI B, PROUET P, et al. Acute megakaryocytic leukemia: what have we learned[J]. Blood Rev, 2016, 30(1): 49-53. doi: 10.1016/j.blre.2015.07.005
[13]	刘彦权, 殷悦, 陈玉婷, 等. 急性巨核细胞白血病14例临床分析并文献复习[J]. 解放军医学杂志, 2022, 47(10): 1006-1012. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY202210014.htm LIU Y Q, YIN Y, CHEN Y T, et al. Clinical analysis and literature review of 14 patients with acute megakaryocytic leukemia[J]. Med J Chin PLA, 2022, 47(10): 1006-1012. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY202210014.htm
[14]	程文文, 路卯, 高艳, 等. 原发性骨髓纤维化转化为急性巨核细胞白血病一例并文献复习[J]. 白血病·淋巴瘤, 2017, 26(8): 491-493. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202403040.htm CHEN W W, LU M, GAO Y, et al. Acute megakaryocytic leukemia transformed from primary myelofibrosis: report of one case and review of literature[J]. Journal of Leukemia & Lymphoma, 2017, 26(8): 491-493. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202403040.htm
[15]	LING T, CRISPINO J D, ZINGARIELLO M, et al. GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy[J]. Expert Rev Hematol, 2018, 11(3): 169-184. doi: 10.1080/17474086.2018.1436965
[16]	ADACHI Y, YAMAGUCHI Y, SAGOU K, et al. Acute megakaryoblastic leukemia developing as donor cell leukemia after umbilical cord blood transplantation[J]. Intern Med, 2018, 57(4): 569-574. doi: 10.2169/internalmedicine.9005-17
[17]	NGUYEN L X T, TROADEC E, KALVALA A, et al. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML[J]. J Cell Physiol, 2019, 234(8): 14040-14049. doi: 10.1002/jcp.28091
[18]	DINARDO C D, PRATZ K, PULLARKAT V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019, 133(1): 7-17. doi: 10.1182/blood-2018-08-868752
[19]	DINARDO C D, JONAS B A, PULLARKAT V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia[J]. N Engl J Med, 2020, 383(7): 617-629. doi: 10.1056/NEJMoa2012971
[20]	MEI M, ALDOSS I, MARCUCCI G, et al. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use[J]. Am J Hematol, 2019, 94(3): 358-362. doi: 10.1002/ajh.25369
[21]	JIA Y N, LIN D, WANG Z, et al. Diagnostic challenge in mixed phenotype acute leukemia with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3)[J]. Diagn Pathol, 2022, 17(1): 74-80. doi: 10.1186/s13000-022-01257-w
[22]	GAUT D, BURKENROAD A, DUONG T, et al. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: a single institution experience[J]. Leuk Res, 2020, 90: 106314-106318. doi: 10.1016/j.leukres.2020.106314
[23]	娄典, 刘利, 秦炜炜. 维奈克拉联合阿扎胞苷治疗老年初治急性髓系白血病的临床分析[J]. 中国肿瘤临床, 2022, 49(15): 775-780. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL202215004.htm LOU D, LIU L, QIN W W. Clinical analysis of venetoclax combined with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia[J]. Chin J Clin Oncol, 2022, 49(15): 775-780. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL202215004.htm
[24]	王菲, 孟小莉, 王丛丛, 等. 维奈克拉治疗老年人继发性急性巨核细胞白血病1例并文献复习[J]. 白血病·淋巴瘤, 2022, 31(1): 55-57. WANG F, MENG X L, WANG C C, et al. Venetoclax in treatment of elderly patients with secondary acute megakaryoblastic leukemia: report of 1 case and review of literature[J]. Journal of Leukemia & Lymphoma, 2022, 31(1): 55-57.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2)

Get Citation

PDF

XML

Article Metrics

Article views (167) PDF downloads(4)

Venetoclax combined with azacitidine in treatment of acute megakaryoblastic leukemia transformed from primary myelofibrosis: report of 1 case and review of literature

doi: 10.16766/j.cnki.issn.1674-4152.003441

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Venetoclax combined with azacitidine in treatment of acute megakaryoblastic leukemia transformed from primary myelofibrosis: report of 1 case and review of literature

doi: 10.16766/j.cnki.issn.1674-4152.003441

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content